Ikena Oncology Inc. (IKNA)
1.20
0.06 (5.26%)
At close: Apr 22, 2025, 3:58 PM
1.18
-1.97%
Pre-market: Apr 23, 2025, 07:44 AM EDT
5.26% (1D)
| Bid | 1.09 |
| Market Cap | 48.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.23M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -1.18 |
| Forward PE | -1.47 |
| Analyst | Hold |
| Ask | 1.28 |
| Volume | 92,044 |
| Avg. Volume (20D) | 114,109 |
| Open | 1.10 |
| Previous Close | 1.14 |
| Day's Range | 1.11 - 1.22 |
| 52-Week Range | 0.97 - 1.94 |
| Beta | 0.48 |
About IKNA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-1...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol IKNA
Website https://ikenaoncology.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IKNA stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 150.00% from the latest price.
Stock Forecasts10 months ago
+25.56%
Ikena Oncology shares are trading higher after the...
Unlock content with
Pro Subscription
10 months ago
Ikena Oncology shares are trading higher after the company announced it will discontinue development of IK-930 and evaluate strategic options for both the Company and its development pipeline.
